Scholarlink

<p>Orexins are hypothalamic neuropeptides primarily involved in regulating the sleep/wakefulness cycle and circadian rhythm. They bind to the orexin receptor type 1 (OX<sub>1</sub>) and type 2 (OX<sub>2</sub>), well-known drug targets in the treatment of sleep disorders,&#xa0;that have recently been shown to play a significant role in different cancers. Lemborexant is one of a few orexin receptor antagonists that have been approved for the treatment of insomnia. Despite being classified as an antagonist, lemborexant may display agonist-like behavior in the non-canonical signaling pathway of the orexin receptors, as confirmed recently in cancer cell models. Here, we generated a model of OX<sub>2</sub> in complex with the full-length G<sub>q</sub> protein and used it in the molecular dynamics (MD) study. We compared the impact of lemborexant and the OX<sub>2</sub>-selective, potent agonist compound 1 on OX<sub>2</sub> activation and subsequent guanosine diphosphate (GDP) to guanosine triphosphate (GTP) exchange in the Gα<sub>q</sub> subunit. These 2&#xa0;µs MD simulations showed that both ligands evoke similar, activation-like conformational changes in OX<sub>2</sub> and explained the observed lemborexant-mediated apoptosis of cancer cells. In addition,&#xa0;MD simulations of the active-state OX<sub>2</sub>-G<sub>q</sub> complexes allowed us to uncover a sequence of micro- and macroscale events during the activation of G<sub>q</sub>&#xa0;and to detect important micro- and macroswitches in the Gα subunit.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Non-canonical Gq activation by orexin receptor type 2 and lemborexant observed in microsecond molecular dynamics simulations

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月22日

查看全文
  • Paulina Dragan,
  • Valerie Gratio,
  • Thierry Voisin,
  • Alain Couvineau,
  • Dorota Latek

摘要

Orexins are hypothalamic neuropeptides primarily involved in regulating the sleep/wakefulness cycle and circadian rhythm. They bind to the orexin receptor type 1 (OX1) and type 2 (OX2), well-known drug targets in the treatment of sleep disorders, that have recently been shown to play a significant role in different cancers. Lemborexant is one of a few orexin receptor antagonists that have been approved for the treatment of insomnia. Despite being classified as an antagonist, lemborexant may display agonist-like behavior in the non-canonical signaling pathway of the orexin receptors, as confirmed recently in cancer cell models. Here, we generated a model of OX2 in complex with the full-length Gq protein and used it in the molecular dynamics (MD) study. We compared the impact of lemborexant and the OX2-selective, potent agonist compound 1 on OX2 activation and subsequent guanosine diphosphate (GDP) to guanosine triphosphate (GTP) exchange in the Gαq subunit. These 2 µs MD simulations showed that both ligands evoke similar, activation-like conformational changes in OX2 and explained the observed lemborexant-mediated apoptosis of cancer cells. In addition, MD simulations of the active-state OX2-Gq complexes allowed us to uncover a sequence of micro- and macroscale events during the activation of Gq and to detect important micro- and macroswitches in the Gα subunit.